ES2723273T3 - Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos - Google Patents
Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos Download PDFInfo
- Publication number
- ES2723273T3 ES2723273T3 ES13707085T ES13707085T ES2723273T3 ES 2723273 T3 ES2723273 T3 ES 2723273T3 ES 13707085 T ES13707085 T ES 13707085T ES 13707085 T ES13707085 T ES 13707085T ES 2723273 T3 ES2723273 T3 ES 2723273T3
- Authority
- ES
- Spain
- Prior art keywords
- proteins
- rabies
- made therefrom
- vectors expressing
- vaccines made
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
- C12N15/8633—Avian poxviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Composición que comprende: a) un vector de ALVAC que comprende un polinucleótido que codifica: i. cuatro polipéptidos G de la rabia que tienen la secuencia como se expone en SEQ ID NO: 1, en los que dos de los polipéptidos G de la rabia están codificados por una parte del polinucleótido insertado en el locus C5 del vector de ALVAC y dos de los polipéptidos G de la rabia están codificados por una parte del polinucleótido insertado en el locus C3 del vector de ALVAC; y ii. un polipéptido OX40L que tiene la secuencia como se expone en SEQ ID NO: 12, en el que el polipéptido OX40L está codificado por una parte del polinucleótido insertado en el locus C6 del vector de ALVAC; y b) un vehículo, diluyente o excipiente farmacéuticamente o veterinariamente aceptable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261598610P | 2012-02-14 | 2012-02-14 | |
PCT/US2013/026206 WO2013123242A1 (en) | 2012-02-14 | 2013-02-14 | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2723273T3 true ES2723273T3 (es) | 2019-08-23 |
Family
ID=47757705
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES13707085T Active ES2723273T3 (es) | 2012-02-14 | 2013-02-14 | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos |
ES18208513T Active ES2866108T3 (es) | 2012-02-14 | 2013-02-14 | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES18208513T Active ES2866108T3 (es) | 2012-02-14 | 2013-02-14 | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos |
Country Status (13)
Country | Link |
---|---|
US (2) | US9567606B2 (es) |
EP (2) | EP3466443B1 (es) |
JP (1) | JP6260972B2 (es) |
CN (1) | CN104203271B (es) |
AU (1) | AU2013221502C1 (es) |
BR (1) | BR112014020019A8 (es) |
CA (1) | CA2864119C (es) |
EA (1) | EA032389B1 (es) |
ES (2) | ES2723273T3 (es) |
HK (1) | HK1200327A1 (es) |
MX (1) | MX360415B (es) |
NZ (2) | NZ628270A (es) |
WO (1) | WO2013123242A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009111738A2 (en) | 2008-03-06 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Single cycle replicating adenovirus vectors |
NZ628270A (en) | 2012-02-14 | 2016-09-30 | Merial Inc | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
BR112015018989B1 (pt) | 2013-02-22 | 2023-11-14 | Curevac Ag | Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna |
US10196435B2 (en) * | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
MX2020010248A (es) * | 2013-12-20 | 2020-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Variante del virus prrs, clon de adnc del virus europeo y sus usos. |
CN103877570B (zh) * | 2014-02-19 | 2016-01-20 | 北京中联康生物科技有限公司 | 狂犬病活疫苗和制备狂犬病口服活疫苗的方法 |
US10307472B2 (en) | 2014-03-12 | 2019-06-04 | Curevac Ag | Combination of vaccination and OX40 agonists |
NZ731659A (en) * | 2014-11-03 | 2018-10-26 | Merial Inc | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
RU2714157C2 (ru) * | 2015-02-06 | 2020-02-12 | Хит Байолоджикс, Инк. | Вектор, коэкспрессирующий молекулы для вакцинации и костимулирующие молекулы |
PL3458474T3 (pl) | 2016-05-18 | 2022-11-14 | Modernatx, Inc. | Kombinacje mrna kodujących polipeptydy immunomodulujące i ich zastosowania |
WO2018071405A1 (en) | 2016-10-11 | 2018-04-19 | University Of Miami | Vectors and vaccine cells for immunity against zika virus |
CA3058938A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
AU2019223768A1 (en) | 2018-02-23 | 2020-08-27 | Boehringer Ingelheim Animal Health USA Inc. | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
CN111518776A (zh) * | 2020-04-16 | 2020-08-11 | 大理大学 | 一种重组狂犬病病毒疫苗株及其制备方法 |
GB202012331D0 (en) * | 2020-08-07 | 2020-09-23 | Petmedix Ltd | Therapeutic antibodies |
US11149286B1 (en) * | 2020-08-17 | 2021-10-19 | Mayo Foundation For Medical Education And Research | Adenovirus vectors and methods for using adenovirus vectors |
WO2023152486A1 (en) * | 2022-02-09 | 2023-08-17 | Petmedix Ltd | Therapeutic antibodies |
CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2909462A (en) | 1955-12-08 | 1959-10-20 | Bristol Myers Co | Acrylic acid polymer laxative compositions |
US5505941A (en) | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
JPS60500673A (ja) | 1983-03-08 | 1985-05-09 | コモンウエルス セラム ラボラトリ−ズ コミツシヨン | 抗原活性を有するアミノ酸配列 |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US6309647B1 (en) * | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
US5756102A (en) | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
US5843456A (en) | 1991-03-07 | 1998-12-01 | Virogenetics Corporation | Alvac poxvirus-rabies compositions and combination compositions and uses |
FR2724385B1 (fr) | 1994-08-29 | 1996-12-13 | Rhone Merieux | Vaccin de la peritonite infectieuse feline. |
WO1996034109A1 (en) | 1995-04-25 | 1996-10-31 | Vical Incorporated | Single-vial formulations of dna/lipid complexes |
US5846946A (en) | 1996-06-14 | 1998-12-08 | Pasteur Merieux Serums Et Vaccins | Compositions and methods for administering Borrelia DNA |
FR2751229B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins |
FR2751224B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs |
FR2751228B1 (fr) | 1996-07-19 | 1998-11-20 | Rhone Merieux | Vaccin polynucleotidique bovin pour voie intradermique |
FR2751225B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique aviaire |
FR2751226B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies du cheval |
FR2751227B1 (fr) | 1996-07-19 | 1998-11-27 | Rhone Merieux | Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives |
WO2002036170A2 (en) * | 2000-11-03 | 2002-05-10 | Oxford Biomedica (Uk) Limited | Vector system for transducing the positive neurons |
CZ299473B6 (cs) | 1997-06-30 | 2008-08-06 | Rhone-Poulenc Rorer S. A. | Nukleová kyselina a elektrické pole jako sdruženýprodukt pro prenos nukleové kyseliny do bunek prícne pruhovaného svalstva |
FR2775601B1 (fr) | 1998-03-03 | 2001-09-21 | Merial Sas | Vaccins vivants recombines et adjuves |
US6497883B1 (en) | 1999-06-10 | 2002-12-24 | Merial | Porcine circovirus recombinant poxvirus vaccine |
US6541458B1 (en) | 1999-07-16 | 2003-04-01 | Merial | Feline calicivirus genes and vaccines in particular recombinant vaccines |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
US7740863B2 (en) | 2001-04-06 | 2010-06-22 | Merial | Recombinant vaccine against West Nile Virus |
CA2570156C (en) | 2004-06-04 | 2014-09-30 | Merial Limited | Needle-free administration of felv vaccines |
ES2424847T3 (es) | 2004-06-25 | 2013-10-09 | Merial Ltd. | Genes del virus de la fiebre aftosa que expresan avipox recombinantes |
US8980280B2 (en) | 2005-03-30 | 2015-03-17 | Merial, Inc. | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
ES2343270T3 (es) | 2005-04-25 | 2010-07-27 | Merial Ltd. | Vacunas contra el virus nipah. |
US7384642B2 (en) | 2005-08-25 | 2008-06-10 | Merial Limited | Canine influenza vaccines |
US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
US8008268B2 (en) | 2006-07-25 | 2011-08-30 | Merial Limited | Vaccines against vesicular stomatitis |
US7910112B2 (en) | 2006-11-06 | 2011-03-22 | Merial Limited | Feline vaccines against avian influenza |
BRPI0719078A2 (pt) | 2006-11-21 | 2013-12-03 | Merial Ltd | Vacina contra leishmania canina |
PT2358742T (pt) | 2008-10-24 | 2018-06-04 | Univ California | Vacina contra vírus da peste equina africana |
CN101884793A (zh) * | 2010-06-29 | 2010-11-17 | 中国人民解放军第三军医大学 | 乙肝病毒核心抗原的免疫增强型基因疫苗及其制备方法 |
NZ628270A (en) | 2012-02-14 | 2016-09-30 | Merial Inc | Recombinant poxviral vectors expressing both rabies and ox40 proteins, and vaccines made therefrom |
-
2013
- 2013-02-14 NZ NZ628270A patent/NZ628270A/en not_active IP Right Cessation
- 2013-02-14 CA CA2864119A patent/CA2864119C/en active Active
- 2013-02-14 US US13/767,603 patent/US9567606B2/en active Active
- 2013-02-14 NZ NZ722700A patent/NZ722700A/en not_active IP Right Cessation
- 2013-02-14 EP EP18208513.4A patent/EP3466443B1/en active Active
- 2013-02-14 WO PCT/US2013/026206 patent/WO2013123242A1/en active Application Filing
- 2013-02-14 MX MX2014009845A patent/MX360415B/es active IP Right Grant
- 2013-02-14 BR BR112014020019A patent/BR112014020019A8/pt active Search and Examination
- 2013-02-14 EP EP13707085.0A patent/EP2814506B1/en active Active
- 2013-02-14 CN CN201380015514.8A patent/CN104203271B/zh not_active Expired - Fee Related
- 2013-02-14 ES ES13707085T patent/ES2723273T3/es active Active
- 2013-02-14 AU AU2013221502A patent/AU2013221502C1/en not_active Ceased
- 2013-02-14 JP JP2014557782A patent/JP6260972B2/ja active Active
- 2013-02-14 EA EA201400912A patent/EA032389B1/ru not_active IP Right Cessation
- 2013-02-14 ES ES18208513T patent/ES2866108T3/es active Active
-
2015
- 2015-01-23 HK HK15100746.0A patent/HK1200327A1/xx not_active IP Right Cessation
-
2017
- 2017-01-19 US US15/410,588 patent/US10006050B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2814506B1 (en) | 2018-11-28 |
BR112014020019A2 (pt) | 2017-07-04 |
HK1200327A1 (en) | 2015-08-07 |
CA2864119A1 (en) | 2013-08-22 |
JP2015511948A (ja) | 2015-04-23 |
AU2013221502B2 (en) | 2017-10-26 |
CN104203271A (zh) | 2014-12-10 |
ES2866108T3 (es) | 2021-10-19 |
US20130209511A1 (en) | 2013-08-15 |
EA032389B1 (ru) | 2019-05-31 |
US20170137843A1 (en) | 2017-05-18 |
EP3466443A1 (en) | 2019-04-10 |
JP6260972B2 (ja) | 2018-01-17 |
MX360415B (es) | 2018-10-31 |
AU2013221502C1 (en) | 2018-03-01 |
CN104203271B (zh) | 2017-08-25 |
EP2814506A1 (en) | 2014-12-24 |
WO2013123242A1 (en) | 2013-08-22 |
AU2013221502A1 (en) | 2014-08-28 |
US9567606B2 (en) | 2017-02-14 |
NZ628270A (en) | 2016-09-30 |
MX2014009845A (es) | 2015-03-10 |
EP3466443B1 (en) | 2020-12-16 |
CA2864119C (en) | 2022-05-24 |
NZ722700A (en) | 2017-12-22 |
US10006050B2 (en) | 2018-06-26 |
BR112014020019A8 (pt) | 2022-07-12 |
EA201400912A1 (ru) | 2015-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2723273T3 (es) | Vectores poxvirales recombinantes que expresan proteínas de la rabia y OX40 y vacunas fabricadas a partir de los mismos | |
EP4104854A3 (en) | Multivalent vaccines for rabies virus and coronaviruses | |
NZ602278A (en) | Bluetongue virus recombinant vaccines and uses thereof | |
CO2018009120A2 (es) | Genes del factor viii optimizados | |
MX347997B (es) | Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle. | |
MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
AR081856A1 (es) | Vacuna y metodos para reducir una infeccion por campylobacter | |
ES2676542T3 (es) | Composiciones de CDV recombinante y usos de las mismas | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
IL276210B2 (en) | MERS-COV vaccine | |
MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
ZA201707985B (en) | Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine | |
WO2016073595A8 (en) | T cells and dendritic cells for polyomavirus therapy | |
CL2015002741A1 (es) | Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos | |
NZ703297A (en) | Reassortant btv and ahsv vaccines | |
NZ608143A (en) | Recombinant modified vaccinia virus ankara (mva) influenza vaccine | |
WO2012018907A3 (en) | Polypeptides for treating and/or limiting influenza infection | |
IN2015DN03206A (es) | ||
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
AR108014A1 (es) | Vacuna universal para enfermedades virales y método de vacunación | |
RU2015140603A (ru) | Вакцины на основе нуклеопротеина вируса гриппа | |
EA201990719A1 (ru) | Новые промоторы | |
AR095425A1 (es) | Vacuna, uso y procedimiento para prevenir una infección por picornavirus | |
MX2018006347A (es) | Proteinas de fusion fmdv y e2 y usos de ellos. | |
AR100824A1 (es) | Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae |